Introduction
Small RNA therapeutics—encompassing small interfering RNAs (siRNAs), microRNA (miRNA) modulators, and antisense oligonucleotides (ASOs)—have emerged as transformative precision medicine tools for metabolic diseases. These modalities exploit sequence-specific gene silencing to modulate master regulators of lipid metabolism, glucose homeostasis, hepatic lipogenesis, and inflammatory pathways implicated in cardiometabolic and liver-centric disorders 8911. The clinical maturation of hepatocyte-targeted delivery platforms, particularly N-acetylgalactosamine (GalNAc) conjugation, has enabled tissue-selective knockdown with 10–100-fold potency improvements, translating into therapeutically meaningful reductions in cardiovascular risk factors and metabolic dysfunction 2819. This review synthesizes mechanistic insights, clinical evidence from Phase II–III trials, delivery innovations, and precision medicine applications of RNA therapeutics in metabolic diseases, emphasizing cardiometabolic dyslipidemias and nonalcoholic fatty liver disease/steatohepatitis (NAFLD/NASH).
Mechanisms and Molecular Targets in Metabolic Pathways
RISC-Mediated Silencing: siRNA and miRNA Mechanisms
siRNAs leverage the RNA-induced silencing complex (RISC) to achieve sequence-specific mRNA cleavage and degradation. Inclisiran, a first-in-class PCSK9-targeting siRNA, exemplifies this mechanism: GalNAc-conjugated siRNA achieves hepatocyte-specific uptake via the asialoglycoprotein receptor (ASGPR), enabling >90% PCSK9 mRNA knockdown despite circulating for <48 hours, with sustained LDL receptor upregulation for >6 months 15. Similarly, plozasiran (ARO-APOC3) and zodasiran (ARO-ANG3) target apolipoprotein C-III and angiopoietin-like protein 3 (ANGPTL3) mRNA, respectively, yielding 50–70% reductions in triglycerides and VLDL remnants 19.
miRNA therapeutics modulate entire regulatory networks through translational repression and mRNA destabilization. microRNA-22 (miR-22) exhibits dual context-dependent roles in metabolic homeostasis: in certain settings, it promotes lipogenesis and glucose dysregulation, while in others it inhibits pathogenic pathways 4. Therapeutic strategies employ chemically modified antagomiRs (anti-miRNA oligonucleotides) to inhibit overactive miRNAs or miRNA mimics to restore deficient regulatory circuits. However, clinical translation of miRNA therapeutics lags behind siRNA and ASO platforms due to pleiotropic effects (single miRNAs regulate hundreds of mRNA targets), tissue-specific expression variability, and immunogenicity challenges 9.
RNase H1-Mediated Cleavage: Antisense Oligonucleotide Mechanisms
ASOs employ RNase H1-mediated mRNA cleavage or steric blockade to suppress target gene expression. GalNAc-conjugated ASOs targeting PCSK9 (e.g., AZD8233) demonstrate 62–79% LDL-C reductions at optimized doses 19. ApoC-III-targeting ASOs (olezarsen, volanesorsen) achieve 50–88% ApoC-III knockdown, reducing triglycerides by 49–71% and mitigating pancreatitis risk in severe hypertriglyceridemia 131519. Chemical modifications—2′-O-methyl groups, phosphorothioate linkages, constrained ethyl residues—enhance nuclease resistance, pharmacokinetics, and reduce off-target immunogenicity, with the 3-10-3 gapmer design balancing potency and safety 8.
Key Metabolic Targets and Pathway Nodes
Lipid Metabolism:
- PCSK9: Hepatic knockdown prevents LDL receptor degradation, increasing LDL-C clearance by 50–80% 151214.
- ANGPTL3: Inhibits lipoprotein lipase (LPL); RNAi-mediated suppression reduces triglycerides (50–63%), LDL-C (20–48%), and protects against nephrotic syndrome-associated dyslipidemia by restoring LPL activity 71719.
- ApoC-III: Overexpression impairs triglyceride clearance; ASO/siRNA targeting achieves 50–88% knockdown, reducing cardiovascular risk in hypertriglyceridemia 131519.
- Lp(a): Apo(a)-targeting ASOs and siRNAs (olpasiran, pelacarsen, lepodisiran, zerlasiran) achieve 70–101% Lp(a) reductions, addressing a causal cardiovascular risk factor unresponsive to statins 11131519.
Hepatic Lipogenesis and NAFLD/NASH:
- STK25: GalNAc-conjugated ASO targeting serine/threonine kinase 25 suppresses de novo lipogenesis (ACC, ACLY, GPAM expression reduced 2–3-fold), ameliorates steatosis, inflammation, and fibrosis in diet-induced obesity models, and improves insulin sensitivity (HOMA-IR) without systemic toxicity 26.
- DGAT (ION224 ASO): Diacylglycerol acyltransferase inhibition achieves 59% NASH activity score reduction and 36% MASH resolution versus 16% placebo, with 44% achieving ≥50% liver fat reduction (MRI-PDFF) without gastrointestinal side effects 19.
- HSD17B13 (ARO-HSD siRNA): >90% mRNA knockdown reduces hepatic inflammation (ALT ↓46%) and liver fat/stiffness in 33–50% of patients, representing a genetically validated NASH target 19.
Metabolic-Inflammation Crosstalk:
STK25 knockdown reduces oxidative stress (4-HNE adducts, TBARS), improves mitochondrial function (MitoTracker Red staining 3-fold higher), and suppresses macrophage infiltration and stellate cell activation, demonstrating simultaneous modulation of lipogenesis, inflammation, and fibrosis pathways 2618.
Clinical Translation Progress: Efficacy, Safety, and Regulatory Status
PCSK9-Targeting Therapeutics
Inclisiran (Leqvio): FDA- and EMA-approved siRNA achieving placebo-corrected LDL-C reductions of 48–58% by Day 510 in ORION-9/10/11 trials (n=3,660 patients) 119. Dosing advantages (300 mg subcutaneous on Days 1, 90, 270, 450; ~2–3 annual injections) contrast with PCSK9 monoclonal antibodies (26–52 annual injections). Long-term extension data (ORION-8, 36 months) sustained 42–51% LDL-C reductions, with 86.6% achieving <70 mg/dL and 74.6% <50 mg/dL targets 1. An "inclisiran first" strategy post-acute coronary syndrome achieved 60% baseline reduction versus 7% usual care (p<0.001) 1. Safety meta-analysis (7 RCTs, n=4,790, mean 15.8 months) confirmed no increased all-cause mortality (RR 0.92, 95% CI 0.54–1.54), major adverse cardiovascular events (RR 0.98, 95% CI 0.82–1.17), or new-onset diabetes (RR 1.02, 95% CI 0.85–1.21), with injection-site reactions (RR 6.50, 95% CI 3.20–13.20) as the primary adverse event—predominantly mild, transient erythema/swelling 3.
AZD8233 (ASO): Phase IIb trials demonstrated 62–79% LDL-C reductions, but development was discontinued due to dose-dependent hepatotoxicity (4/29 patients with ALT >3×ULN at 90 mg weekly) 19.
ApoC-III Targeting: Triglyceride Reduction
Plozasiran (siRNA): Phase IIb trials (SHASTA-2, MUIR) confirmed 49–62% triglyceride and 57–79% ApoC-III reductions sustained through 15-month extensions 19.
Olezarsen and Volanesorsen (ASOs): Olezarsen achieved 49–53% triglyceride reductions (50–80 mg monthly) with uncommon hepatic/renal abnormalities 19. Volanesorsen (earlier-generation ASO) demonstrated 71% triglyceride reduction but 13% discontinued due to injection-site reactions, and 15% experienced injection-site reactions per dose—prompting transition to GalNAc-conjugated chemistries 1319.
Lp(a) Targeting: Addressing Residual Cardiovascular Risk
Olpasiran (siRNA): Phase II data (n=290) showed dose-dependent Lp(a) reductions of 70.5% (10 mg), 97.4% (75 mg), and 101.1% (225 mg quarterly), with >98% of patients on ≥75 mg achieving Lp(a) ≤125 nmol/L 19. Lepodisiran: Quarterly 400 mg dosing achieved 94% reduction at 60–180 days, sustained at 74% by 540 days (18 months) 19. Zerlasiran: 300 mg every 16 weeks or 450 mg every 24 weeks achieved 82–86% time-averaged reductions through 36 weeks 19. Cardiovascular outcome trials are ongoing to confirm clinical benefit beyond surrogate Lp(a) lowering.
ANGPTL3 Targeting: Dual Lipid Modulation
Zodasiran (siRNA): Mixed dyslipidemia trial (n=204) demonstrated 51–63% triglyceride and 20% LDL-C reductions (200 mg dose) 19. In homozygous familial hypercholesterolemia (HoFH, n=18), 200–300 mg doses achieved 44–48% LDL-C reductions atop maximal therapy 19. Vupanorsen (ASO): Development halted despite 42–57% triglyceride reductions due to dose-dependent hepatic fat accumulation (up to 76%) and ALT elevations (up to 44% >3×ULN) 19.
NASH Therapeutics
ION224 (DGAT ASO): Phase II trial (n=160) achieved primary endpoint of ≥2-point NASH activity score reduction in 58.8% (120 mg) versus 18.8% placebo (p<0.001), with MASH resolution in 35.6% versus 15.6% and ≥50% liver fat reduction in 44% versus 3% 19. ARO-HSD (HSD17B13 siRNA): Phase I/II data demonstrated >90% mRNA knockdown (200 mg), 46% ALT reduction, and 4–41% liver fat/stiffness reductions in 33–50% of patients, with no drug-related serious adverse events 19.
Delivery Technologies and Tissue Targeting
GalNAc Conjugation: Hepatocyte-Specific Precision
GalNAc triantennary conjugates target hepatocyte ASGPR with 10–100-fold potency improvements versus unconjugated oligonucleotides 28. GalNAc-STK25 ASO achieved ED50 of 0.2 mg/kg/week versus 2.3 mg/kg/week unconjugated (preclinical) 2. GalNAc-ANGPTL3 siRNA relieved LPL inhibition in nephrotic syndrome rats, reducing hypertriglyceridemia, proteinuria, and renal inflammation without systemic off-target effects 17. This platform enables subcutaneous self-administration and quarterly to biannual dosing 819.
Lipid Nanoparticles and Extrahepatic Delivery
Lipid nanoparticles (LNPs) with ionizable lipids facilitate endosomal escape but remain largely hepatotropic 8. Extrahepatic delivery to adipose, muscle, pancreas, and kidney remains a critical gap. Ongoing research explores peptide/antibody conjugates and organ-specific ligands 811.
Biomarkers for Target Engagement
Target mRNA knockdown (>70–90% hepatic suppression), plasma protein reductions (PCSK9, ANGPTL3, ApoC-III, Lp(a)), and imaging biomarkers (MRI-PDFF for liver fat, FibroScan for stiffness) validate pharmacodynamic effects 219.
Safety Profile and Risk Management
Class-Specific Adverse Events
Injection-Site Reactions: GalNAc-conjugated siRNAs exhibit 2–13% incidence (mild, transient) versus earlier-generation ASOs (13–33%) 319. Inclisiran injection-site reactions (5% versus 0.7% placebo) rarely necessitate discontinuation 13.
Hepatic Signals: Dose-dependent ALT elevations observed with PCSK9 ASO AZD8233 (13.8% >3×ULN at 90 mg) and ANGPTL3 ASO vupanorsen (44% >3×ULN at high doses, plus 76% hepatic fat increase) led to program discontinuations 19. Notably, NASH-targeted ASO ION224 reduced ALT/AST, demonstrating therapeutic benefit 19.
Platelet/Renal Effects: Earlier-generation ASO volanesorsen raised historical concerns, but GalNAc-conjugated programs (plozasiran, olezarsen) show no significant platelet or renal abnormalities 1319.
Cardiovascular Events: Meta-analysis confirmed inclisiran does not increase major adverse cardiovascular events (RR 0.98, 95% CI 0.82–1.17), with numerically lower myocardial infarction rates in ORION trials 319.
Long-Term Safety: Median trial durations (15.8 months) necessitate 5–10-year post-marketing surveillance for chronic disease management 3. ORION-8 extension (36 months) and ongoing ORION-4/VICTORION outcome trials will address this gap 13.
Precision Metabolic Medicine: Patient Selection, Combination Strategies, and Future Directions
Biomarker-Driven Patient Stratification
Genetic Substratification: Homozygous familial hypercholesterolemia (HoFH) patients achieved 44–48% LDL-C reductions with ANGPTL3 siRNA atop maximal therapy, demonstrating efficacy in monogenic severe dyslipidemia 19. Loss-of-function PCSK9 mutations confer lifelong LDL-C reduction and cardiovascular protection, validating therapeutic targeting 512. HSD17B13 loss-of-function variants protect against NASH progression, supporting ARO-HSD siRNA development 19.
Baseline Lipid Phenotypes: Severe hypertriglyceridemia (TG ≥500 mg/dL) responds robustly to ApoC-III targeting (71% reduction, 82% achieving TG <500 mg/dL pancreatitis threshold) 19. Elevated Lp(a) >50 mg/dL identifies patients for apo(a)-targeting therapies, independent of LDL-C control 111315.
Comorbidity Context: Nephrotic syndrome dyslipidemia responds to ANGPTL3 RNAi (hypertriglyceridemia, proteinuria, and renal inflammation reduced) 17. NAFLD with type 2 diabetes benefits from combined metabolic pathway modulation (STK25, DGAT targeting) 2618.
Combination Therapy Rationales
Modeling predicts inclisiran + high-intensity statin + ezetimibe + bempedoic acid achieves 85% LDL-C reduction, enabling patients with baseline LDL-C up to 466 mg/dL to reach <55 mg/dL targets 1. ApoC-III and ANGPTL3 targeting may synergize with GLP-1/GIP agonists (weight reduction, insulin sensitization) and SGLT2 inhibitors (cardiorenal protection) in metabolic syndrome 18.
Adoption Barriers and Real-World Implementation
Cost-Effectiveness: High acquisition costs (comparable to PCSK9 monoclonal antibodies) require health-economic justification via cardiovascular outcome trials and adherence advantages from infrequent dosing (2–4 annual injections vs. 26–52) 1513.
Access and Equity: Real-world registries (Imperial College London, Italy, Israel, Netherlands, Germany) confirm 38–49% mean LDL-C reductions with inclisiran, validating trial efficacy 1. Expansion to low/middle-income countries requires manufacturing scale-up and pricing strategies.
Post-Marketing Surveillance: Regulatory agencies (FDA, EMA, NMPA) emphasize manufacturing consistency, immunogenicity monitoring, and long-term safety surveillance for RNA therapeutics 58.
Next-Wave Research and Development Directions
Multi-Target and Pathway-Level Modulation: Simultaneous targeting of interconnected metabolic pathways (e.g., lipogenesis + inflammation + mitochondrial function via STK25, DGAT, HSD17B13) may yield synergistic NASH/MASH benefits 2618.
Allele-Specific Silencing: Targeting gain-of-function variants (e.g., PCSK9 D374Y) or selectively suppressing pathogenic alleles in heterozygous familial hypercholesterolemia.
Epigenetic and Base Editing: Epigenetic editing of PCSK9 offers reversible gene suppression without DNA sequence alteration 16. Base editing achieved PCSK9 knockdown and LDL-C reduction in first-in-human trials, though off-target effects and long-term safety require rigorous monitoring 10.
Extrahepatic Delivery: Adipose-targeted delivery for adipokine modulation (leptin, adiponectin), muscle-targeted delivery for insulin resistance, and pancreatic β-cell delivery for diabetes remain unmet needs 811.
Programmable RNA Platforms: Self-amplifying RNA, circular RNA, and CRISPR-based approaches may enable durable, regulatable expression control 11.
Trial Design Innovations: Cardiovascular outcome trials (ORION-4, VICTORION-1/2/PLAQUE) will establish whether surrogate lipid reductions translate to clinical benefit 13. Adaptive platform trials testing combinations and biomarker-enriched populations will accelerate translation 19.
Conclusion
Small RNA therapeutics have transitioned from experimental tools to clinically validated precision medicines for metabolic diseases, with GalNAc-conjugated hepatocyte-targeted siRNAs and ASOs achieving regulatory approval (inclisiran) or late-stage development (plozasiran, olezarsen) for cardiometabolic dyslipidemias. Mechanistically, these platforms exploit sequence-specific RISC-mediated or RNase H1-mediated silencing of master metabolic regulators (PCSK9, ANGPTL3, ApoC-III, STK25, DGAT, HSD17B13), yielding 50–100% reductions in pathogenic lipids/proteins with favorable safety profiles dominated by mild injection-site reactions. Delivery innovations—particularly GalNAc conjugation enabling 10–100-fold potency improvements and quarterly to biannual dosing—address long-standing adherence challenges in chronic disease management. Precision metabolic medicine integration requires biomarker-driven patient selection (genetic variants, baseline lipid phenotypes, comorbidities), rational combination strategies with existing therapies, and long-term cardiovascular outcome evidence.
Future directions emphasize extrahepatic delivery for adipose/muscle/pancreatic targets, multi-pathway modulation for NASH/MASH, epigenetic/base-editing approaches for durable effects, and adaptive trial designs. As the field matures, RNA therapeutics are poised to redefine precision medicine in metabolic diseases, transforming cardiovascular risk reduction and metabolic dysfunction management through tissue-selective, durable, and mechanistically rational interventions.